Injunction Stops Sales Of Qiagen GeneReader
The system was launched late last year, but a preliminary injunction issued by a federal court in California will now block Qiagen from marketing its GeneReader sequencing system in the US. Illumina had filed a patent claim against the system, and the court found that the claim is likely to succeed.
You may also be interested in...
Qiagen has acquired privately held Intelligent Bio-Systems, a developer of next-generation sequencing (NGS) instruments aimed at the clinical research market. IBS’ technology, along with a newly expanded collaboration with bioinformatics provider SAP, is the cornerstone of a new NGS initiative at Qiagen.
The device giant is recalling Cobalt and Crome defibrillators because they may deliver weaker shocks than intended.
Agency won’t require manufacturers to submit class I devices to the database for an extra 75 days, and doesn't plan to enforce GUDID regulations against consumer health products.